- Home
- BILI vs MDGL Comparison
BILI vs MDGL Comparison
Compare BILI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILI
- MDGL
- Stock Information
- Founded
- BILI 2009
- MDGL 2011
- Country
- BILI China
- MDGL United States
- Employees
- BILI N/A
- MDGL N/A
- Industry
- BILI EDP Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- BILI Technology
- MDGL Health Care
- Exchange
- BILI Nasdaq
- MDGL Nasdaq
- Market Cap
- BILI 11.2B
- MDGL 9.6B
- IPO Year
- BILI 2018
- MDGL N/A
- Fundamental
- Price
- BILI $30.07
- MDGL $405.34
- Analyst Decision
- BILI Buy
- MDGL Strong Buy
- Analyst Count
- BILI 7
- MDGL 12
- Target Price
- BILI $28.00
- MDGL $521.09
- AVG Volume (30 Days)
- BILI 2.9M
- MDGL 287.6K
- Earning Date
- BILI 11-13-2025
- MDGL 11-04-2025
- Dividend Yield
- BILI N/A
- MDGL N/A
- EPS Growth
- BILI N/A
- MDGL N/A
- EPS
- BILI 0.07
- MDGL N/A
- Revenue
- BILI $4,101,275,719.00
- MDGL $515,547,000.00
- Revenue This Year
- BILI $14.54
- MDGL $394.38
- Revenue Next Year
- BILI $8.91
- MDGL $64.73
- P/E Ratio
- BILI $406.84
- MDGL N/A
- Revenue Growth
- BILI 22.70
- MDGL 3421.98
- 52 Week Low
- BILI $14.47
- MDGL $238.04
- 52 Week High
- BILI $32.50
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- BILI 59.38
- MDGL 40.02
- Support Level
- BILI $29.75
- MDGL $393.61
- Resistance Level
- BILI $30.65
- MDGL $434.98
- Average True Range (ATR)
- BILI 0.76
- MDGL 17.69
- MACD
- BILI 0.12
- MDGL -3.22
- Stochastic Oscillator
- BILI 64.35
- MDGL 24.71
About BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.